
Mark Augspurger, MD Office and Other Patient Information
Mark Augspurger, MD Biography and Info
Mark Augspurger, MD, specialized in radiation oncology in order to utilize the latest advances in technology to cure cancer and improve the lives of his patients. Dr. Augspurger advocates for a team approach, bringing physicians from multiple specialties together to provide the best care for patients. His areas of expertise are:
- Head and Neck Cancer
- Lung and Esophageal Cancer
- Rectal and Anal Cancer
- Gynecological and Breast Cancer
- Bladder and Prostate Cancer
- Brain and Spine Cancers
- Pediatric Cancers
About Me
I am a Jacksonville native. I graduated from Terry Parker High School and attended the University of Florida for both undergraduate studies and medical school, go Gators! After completing my service with the United States Air Force, I was fortunate to be able to return to practice in my hometown. When not taking care of patients, I am usually spending time with my two sons. We enjoy fishing, camping and participating in activities with the Boys Scouts of America.
My philosophy of care centers on the patient as an individual. Patients with cancer are not statics; they are human beings with unique lives and goals. I see myself as a guide that has the ability and responsibility to assist each patient under my care on their own individual cancer journey.
I strongly believe in the Jacksonville community and the Baptist Health system and have helped serve the Baptist Health Foundation. I have enjoyed participation in Rotary and I take an active role in mentoring youth through the Boy Scouts of America.
Specialties
- Radiation Oncology
Boards
- American Board of Radiology (Radiation Oncology)
Languages
- English
Hospital Affiliation
- Baptist Medical Center Jacksonville
- Baptist Medical Center Beaches
- Baptist Medical Center South
- Wolfson Children's Hospital
- Baptist Medical Center Clay
Legal Practice Name
- Baptist MD Anderson Cancer Physicians Inc
Ages Treated
- Infant
- Toddler
- Adolescent
- Teen
- Adult
- Senior
Mark Augspurger, MD Additional Information
Education & Training
-
Bachelor of Science - Undergraduate
University of Florida - Gainesville , FL
1988 – 1992
-
Doctor of Medicine - Medical School
University of Florida College of Medicine - Gainesville , FL
1992 – 1995
-
Internship
Georgia Baptist Medical Center - Atlanta , GA
1995 – 1996
-
Residency
Baylor Radiation Oncology Residency - Houston , TX
1996 – 2000
Publications
-
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials. PMID: 40239134
Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL
J Clin Oncol 2025 Apr 16. JCO2400365 doi: 10.1200/JCO.24.00365. Epub 2025 Apr 16.
PMID: 40239134 [PubMed - as supplied by publisher]
-
Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy". PMID: 39970495
Tino RB, Roach MA, Fuentes GD, Agrawal A, Zaid M, Cooper DJ, Bajaj N, Lin R, Xiao L, Mayo LL, Wiederhold LR, Shah SJ, Tate MK, Chronowski GM, Reddy JP, Mezera M, Mann JM, Augspurger M, Otun AO, Chambers MS, Lee A, Koay EJ
Oral Oncol 2025 Mar. 162107220 doi: 10.1016/j.oraloncology.2025.107220. Epub 2025 Feb 18.
PMID: 39970495 [PubMed - in process]
-
Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy. PMID: 39024700
Tino R, Roach MA, Fuentes GD, Agrawal A, Zaid M, Cooper DJ, Bajaj N, Lin R, Xiao L, Mayo LL, Wiederhold LR, Shah SJ, Tate MK, Chronowski GM, Reddy JP, Mezera M, Mann JM, Augspurger M, Otun AO, Chambers MS, Koay EJ
Oral Oncol 2024 Oct. 157106944 doi: 10.1016/j.oraloncology.2024.106944. Epub 2024 Jul 17.
PMID: 39024700 [PubMed - indexed for MEDLINE]
-
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID: 38935373
Chun SG, Hu C, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Kavadi VS, Narayan S, Iyengar P, Robinson C, Rothman J, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD
JAMA Oncol 2024 Aug 1. 10(8)1111-1115 doi: 10.1001/jamaoncol.2024.1841.
PMID: 38935373 [PubMed - indexed for MEDLINE]
-
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529. PMID: 36413683
Kharofa JR, Yothers G, Kachnic LA, Ajani J, Meyer JE, Augspurger ME, Okawara GS, Garg MK, Schefter TE, Swanson TA, Doncals DE, Kim H, Zaki BI, Narayan S, Lee RJ, Mamon HJ, Schwartz MA, Moughan J, Crane CH
Am J Clin Oncol 2022 Dec 1. 45(12)534-536 doi: 10.1097/COC.0000000000000955. Epub 2022 Nov 22.
PMID: 36413683 [PubMed - indexed for MEDLINE]
-
Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy. PMID: 36383379
Magliocco AM, Moughan J, Miyamoto DT, Simko J, Shipley WU, Gray PJ, Hagan MP, Parliament M, Tester WJ, Zietman AL, McCarthy S, Saeed-Vafa D, Xiong Y, Ayral T, Hartford AC, Patel A, Rosenthal SA, Chafe S, Greenberg R, Schwartz MA, Augspurger ME, Keech JA Jr, Winter KA, Feng FY, Efstathiou JA
JAMA Netw Open 2022 Nov 1. 5(11)e2242378 doi: 10.1001/jamanetworkopen.2022.42378. Epub 2022 Nov 1.
PMID: 36383379 [PubMed - indexed for MEDLINE]
-
Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer. PMID: 34400269
Kachnic LA, Winter KA, Myerson RJ, Goodyear MD, Abitbol AA, Streeter OE, Augspurger ME, Schefter TE, Katz AW, Fisher BJ, Henke LE, Narayan S, Crane CH
Int J Radiat Oncol Biol Phys 2022 Jan 1. 112(1)146-157 doi: 10.1016/j.ijrobp.2021.08.008. Epub 2021 Aug 14.
PMID: 34400269 [PubMed - indexed for MEDLINE]
-
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. PMID: 31742674
Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA
Cancer 2020 Feb 1. 126(3)506-514 doi: 10.1002/cncr.32570. Epub 2019 Nov 19.
PMID: 31742674 [PubMed - indexed for MEDLINE]
-
One-Dimensional Carrier Confinement in "Giant" CdS/CdSe Excitonic Nanoshells. PMID: 28535356
Razgoniaeva N, Moroz P, Yang M, Budkina DS, Eckard H, Augspurger M, Khon D, Tarnovsky AN, Zamkov M
J Am Chem Soc 2017 Jun 14. 139(23)7815-7822 doi: 10.1021/jacs.7b02054. Epub 2017 Jun 5.
PMID: 28535356 [PubMed]
-
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. PMID: 28034064
Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD
J Clin Oncol 2017 Jan. 35(1)56-62. Epub 2016 Oct 31.
PMID: 28034064 [PubMed - indexed for MEDLINE]
-
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. PMID: 27022122
Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP
J Clin Oncol 2016 May 10. 34(14)1620-5 doi: 10.1200/JCO.2015.64.8634. Epub 2016 Mar 28.
PMID: 27022122 [PubMed - indexed for MEDLINE]
-
Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. PMID: 14967426
Floyd NS, Woo SY, Teh BS, Prado C, Mai WY, Trask T, Gildenberg PL, Holoye P, Augspurger ME, Carpenter LS, Lu HH, Chiu JK, Grant WH 3rd, Butler EB
Int J Radiat Oncol Biol Phys 2004 Mar 1. 58(3)721-6.
PMID: 14967426 [PubMed - indexed for MEDLINE]
-
Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. PMID: 11173142
Teh BS, Mai WY, Augspurger ME, Uhl BM, McGary J, Dong L, Grant WH 3rd, Lu HH, Woo SY, Carpenter LS, Chiu JK, Butler EB
Int J Radiat Oncol Biol Phys 2001 Feb 1. 49(2)465-72.
PMID: 11173142 [PubMed - indexed for MEDLINE]
-
Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. PMID: 11172952
Teh BS, Mai WY, Uhl BM, Augspurger ME, Grant WH 3rd, Lu HH, Woo SY, Carpenter LS, Chiu JK, Butler EB
Int J Radiat Oncol Biol Phys 2001 Mar 1. 49(3)705-12.
PMID: 11172952 [PubMed - indexed for MEDLINE]
Additional Publications from Mark Augspurger, MD (14 Citations)